The Conversation (0)
Description:
Privately owned research and corporate finance firm Lodge Partners recommends a ‘speculative buy’ for BlinkLab’s (ASX:BB1) autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) diagnostic app.
Lodge Partners’ initial research report also valued BlinkLab at $1.30 using a future and probability-weighted discounted cash flow model.
“We assume BB1’s app has a better than even chance to be commercialised due to having a predicate device on the market and the data on hand. We further assume a minimal penetration rate in the first few years before rising to 10 percent of the diagnostic market by 2031 and pricing of US$250/test,” the report said.
“Similarly, we assume BB1 will penetrate 10 percent of the ADHD diagnostic market by 2031. Using a 15 percent discount rate we find BB1 with a valuation of $1.30/share. This valuation is only based on the US market and has significant upside should we include (the) rest of world.”
BlinkLab’s technology
BlinkLab’s technology for detecting ASD and ADHD targets children from 18 months of age to 72 months. Automated facial recognition and image processing techniques analyse the data and test for several biomarkers which give an indication of the child having ASD or ADHD with high sensitivity and specificity.
Highlights of the Report
- Closest competitors, Cognoa and EarliTec Diagnostics, have measured lower sensitivity and specificity of 52 percent/19 percent and 71 percent/81 percent, respectively.
- The ASD diagnostic market is estimated to grow at a CAGR of 8 percent annually and potentially grow to US$5.4bn by 2036.
- The earlier and faster a child can be diagnosed will lead to better outcomes and it is currently an unmet need.
For the full analyst report, click here.
This content is intended only for persons who reside or access the website in jurisdictions with securities and other applicable laws which permit the distribution and consumption of this content and whose local law recognizes the scope and effect of this Disclaimer, its limitation of liability, and the legal effect of its exclusive jurisdiction and governing law provisions [link to Governing Law section of the Disclaimer page].
Any investment information contained on this website, including third party research reports, are provided strictly for informational purposes, are general in nature and not tailored for the specific needs of any person, and are not a solicitation or recommendation to purchase or sell a security or intended to provide investment advice. Readers are cautioned to seek the advice of a registered investment advisor regarding the appropriateness of investing in any securities or investment strategies mentioned on this website.
BB1:AU
BlinkLab Limited Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
BlinkLab Limited
Investor Insight
BlinkLab’s transformative AI-based healthcare technology is at the forefront of innovations in the global medical field that are quickly gaining traction among keen investors.
Overview
BlinkLab (ASX:BB1) offers a smartphone-based diagnostic platform that leverages computer vision, artificial intelligence (AI) and machine learning (ML). A company started by neuroscientists at Princeton University, Blinklab has developed its novel technology over several years, providing an app-enabled, smartphone-based diagnostic tool for evaluating children with neurodevelopmental conditions such as autism and ADHD.
The app turns a smartphone into a diagnostic tool that helps to conduct remote and rapid tests that can assist in diagnosing neurodevelopmental conditions. BlinkLab’s smartphone app provides a screening tool that can help with diagnoses much earlier than the age that children are typically assessed at present (approximately 5-6 years old). It is also a remote (i.e., accessible) and inexpensive means of beginning the assessment process, which can typically be very costly and take up to multiple years currently.
BlinkLab’s smartphone app facilitates early diagnosis, reduces costs, and improves accuracy.
BlinkLab’s smartphone-based technology, which uses AI and machine learning (ML), makes it attractive to investors. Like other industries, AI is becoming very popular in the healthcare sector. According to Statista, the AI healthcare market is expected to proliferate from $11 billion in 2021 to $187 billion in 2030. The increasing use of AI is driven by advanced ML algorithms, access to data, and use of 5G technology. AI and ML technologies can evaluate and analyze enormous volumes of data faster than humans.
Artificial intelligence, and particularly machine learning, has the potential to serve as the great equaliser for many behavioural healthcare concerns like autism. According to recent data, 97 percent of adults in the United States own a cellular device, and nine in ten own a smartphone. A 2022 Global State of Digital report by We Are Social shows 66.9 percent, or about 5.34 billion, of the world’s population are mobile users. As these percentages continue to rise and internet-powered devices become ubiquitous, access to digital health services can become democratised on a global scale. While autism spectrum disorder (ASD) services are currently restricted to relatively privileged populations, digital solutions powered by emerging data, science, and methodologies can make access to autism therapy more accessible.
Large players are investing in this segment to tap into the vast potential of these new technologies. One such example was Pfizer’s acquisition of ResApp. In October 2022, Pfizer acquired Queensland University startup ResApp Health for $179 million. ResApp developed a smartphone technology to detect respiratory diseases using cough analysis accurately.
Furthermore, big tech companies such as Apple, Amazon, Microsoft and Alphabet are also now venturing into the AI healthcare market.
Company Highlights
- Australia-based BlinkLab (ASX:BB1) is focused on transforming mental healthcare through an AI-enabled smartphone application, a breakthrough technology developed with Princeton University.
- The company’s innovative approach leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention.
- Once approved by regulators, this cutting-edge digital technology is poised to capture the imagination of both investors and major pharmaceutical companies, eager to embrace transformative solutions in healthcare.
- BlinkLab is led by an experienced management team and leading experts in the field of machine learning, autism and brain development, bridging the most advanced technological innovations with groundbreaking scientific research. The company is chaired by Brian Leedman, an experienced biotechnology entrepreneur and founder of ResApp Health, a digital diagnostic company recently acquired by Pfizer.
Key Technology and Applications
Neurobehavioral assays of brain function can reveal fundamental mechanisms underlying neuropsychiatric conditions, but typically require centrally located equipment in a laboratory test facility. Consequently, these tests are often unpleasant for participants, as they often require instruments attached to their face and cannot be used at scale in daily clinical practice, particularly with paediatric patients.
BlinkLab has developed a smartphone-based software platform, known as ‘BlinkLab Test’, to perform neurobehavioural testing that is free from facial instruments or other fixed location equipment.
This AI-based platform is designed to be used at home or in similarly comfortable environments, either independently or with the assistance of a caregiver, while following instructions from the smartphone application. The tests include, but are not limited to, eyeblink conditioning (EBC), which is a form of sensory-motor associative learning, prepulse inhibition of the acoustic startle response (PPI), which measures the ability to filter out irrelevant information through sensorimotor gating, startle habituation, which measures the ability for the intrinsic damping of repetitive stimuli and sensory adaptation, and habituation of the eye blink response, which serve as biomarkers for neurological and psychiatric disorders.
The BlinkLab Test App combines a smartphone’s ability to deliver stimuli and acquire data using computer vision with a secure cloud-based portal for data storage and analysis. In the tests, each audio and/or visual stimulus is presented with millisecond-precise control over parameters such as timing, amplitude and frequency. To maintain participant attention, an entertaining movie of choice is shown with normalised audio levels. Participants’ responses are measured by the smartphone’s camera and microphone, and are processed in real time using state-of-the art computer vision techniques. Response data is then fully anonymised, and transferred securely to the analysis portal. There, BlinkLab’s in-house AI/ML algorithms then perform clustering and statistical analysis to identify the prediction value of the experiment in the particular data set.
BlinkLab Test was initially developed as a prescription diagnostic aid to healthcare professionals (HCP) considering the diagnosis of ASD in patients 18 months through 72 months of age that are at risk for developmental delay. In collaboration with Princeton University in the United States and Erasmus Medical Center in the Netherlands, the company has conducted several trials using BlinkLab Test as an early assessment tool for autism. Autism represents a global challenge, with 1 in 36 children in the U.S. having autism, up from the previous rate of 1 in 44. With no early tests currently available to detect the condition, many children are diagnosed with the condition as late as the age of five.
Blinklab’s mobile app can aid in early detection, facilitating diagnoses as early as two years of age and resulting in earlier personalised interventions and monitoring. The testing process is also far more comfortable than traditional means of diagnoses, as the child can watch their favourite movie or cartoon on the phone, and the app will record their reactions, providing key information on the functioning of the brain.
BlinkLab will be subject to regulatory oversight as a medical device and must clear clinical studies. Previous clinical trials completed by Blinklab have shown impressive indicators of success, achieving sensitivity levels of 85 percent and specificity levels of 84 percent. The company notes that these trials are very similar to those that are required by the United States Food and Drug Administration (FDA) for approval and have shown much higher levels of accuracy compared to currently approved products.
In order for the BlinkLab Test technology to be used as a clinical aid in the diagnosis of ASD, BlinkLab will need to complete a pivotal registrational study, and subsequently apply for FDA registration and reimbursement for the tests. The registrational study intends to recruit up to 500 subjects. Enrolment for this study is expected to begin in 2024, with study completion expected by mid-2025. The potential to participate in a disruptive and scalable AI-powered technology close to regulatory approval should attract attention from big medical technology companies.
Research and clinical studies
BlinkLab engages and partners with research and medical institutions across the globe to further test and develop its technology.
In May 2024, BlinkLab initiated a clinical study in partnership with US-based Turning Pointe Autism Foundation to enroll up to one hundred children previously diagnosed with autism and one hundred children without an autism diagnosis. The data obtained during this collaboration will be used to finalise the data collection and processing algorithms and AI/ML models ahead of the FDA registrational study.
The company is also participating in a clinical study of patients with spinocerebellar ataxias, conducted by Columbia University, New York, to study the effect of aerobic physical exercise on neuroplasticity in adults with spinocerebellar ataxias (SCA).
To further improve and accelerate the diagnostic evaluation of ADHD, BlinkLab forged a major research and clinical partnership with Mental Care Group (MCG) in The Netherlands, the fifth largest outpatient mental health care provider in Europe.
To validate BlinkLab’s platform for the assessment of functional neurological disorder (FND), the company has partnered with Bates College in Maine for a clinical study that aims to characterise the behavioural time course of Pavlovian eyeblink conditioning and acoustic startle habituation. It will validate the BlinkLab smartphone test for use as a remote neurobehavioral testing and diagnostic tool for FND.
At Erasmus University Medical Center, BlinkLab’s smartphone-based remote assessment, including eyeblink conditioning and prepulse inhibition of the acoustic startle reflex, is being used, among other tools, in a clinical study to set-up an overarching at-home testing lab, named the Digital Dementia Lab, to identify, develop and test a variety of digital biomarkers
measuring clinically relevant behaviour for improving early accurate diagnosis of dementia.
BlinkLab is also working with Monash University in Australia to evaluate BlinkLab as a medical device for monitoring the therapeutic effects of ketamine on cognitive processes whereby sensory information is converted into decision making. Results from this study can help facilitate cognitive behavioural therapy outcomes in patients with psychiatric conditions such as depression, schizophrenia, epilepsy, and post-traumatic stress disorder.
BlinkLab also recently signed a partnership for more clinical trialling with INTER-PSY, a large centre in the Netherlands that specialises in autism, offering assistance with diagnostics and treatments. This study also mirrors the study design of the Company’s developing FDA regulatory trial, which will be needed for future approval of BlinkLab Test as an approved diagnostic tool in the United States.
Management Team
BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. The company’s chairman, Brian Leedman, is an experienced biotechnology entrepreneur and founder of ResApp Health, a digital diagnostic company for respiratory conditions, which was recently acquired by Pfizer for $179 million before reaching FDA approval for their main diagnostic product.
Dr. Henk-Jan Boele – Founder and Chief Executive Officer
Henk-Jan Boele is an assistant professor of neuroscience at the Medical Center of Erasmus University and a researcher at Princeton University. He obtained his PhD from Erasmus University in 2014. Boele has always been pushing scientific and methodological boundaries, and received numerous government and industry grants in the field of neuroscience.
Peter Boele – Founder and Chief Technology Officer
Peter Boele holds a bachelor’s degree in history and philosophy from Leiden University. He has over 20 years of experience in software development and has worked with Erasmus University, Leaseweb, Kaboom Informatics and Insocial.
Dr. Anton Uvarov – Founder and Chief Operational Officer
Anton Uvarov holds a Ph.D. from the University of Manitoba and an MBA from the Haskayne School of Business. He has rich experience in bio-technology investments with a particular focus on neuroscience and has successfully led several IPOs. He started his career as a biotechnology analyst with Citigroup, US.
Dr. Bas Koekkoek – Founder and Chief Scientific Officer
Bas Koekkoek is an assistant professor at Erasmus Medical Center. Koekkoek has been working at the Department of Neuroscience mainly in the role of rapid prototype of new technology and techniques for neuroscience. He has numerous publications in the area of brain development including Nature and Science journals.
Professor Sam Wang – Founder and Chair of Advisory Board
Sam Wang holds a PhD from Stanford University. He is a professor of neuroscience at Princeton University, has published over 100 articles on the brain in leading scientific journals and has received numerous awards. He gives public lectures on a regular basis and has been featured in The New York Times, The Wall Street Journal, NPR, and the Fox News Channel.
Professor Chris de Zeeuw – Founder and Scientific Advisor
Chris de Zeeuw is chairman of the Department of Neuroscience at Erasmus MC in Rotterdam and vice-director at the Netherlands Institute for Neuroscience in Amsterdam. De Zeeuw has received over 100 grants, including the Pioneer Award from ZonMw and the ERC advanced grant. In 2006, he received the Beatrix Award for Brain Research from Her Majesty the Queen; in 2014, he became an elected member of the Dutch Academy of Arts & Science; and in 2018, he received the international Casella Prize for Physiology.
Syntheia
Investor Insight
Syntheia’s innovative conversational AI solution is transforming the face of customer engagement for the B2B market. Backed by a stable financial foundation, Syntheia is well-placed to execute its growth strategy, offering investors a compelling opportunity.
Overview
Syntheia (CSE:SYAI) has rapidly emerged as an innovative player in the expanding conversational AI platform-as-a-service market.
In an industry poised to transform customer engagement, Syntheia addresses the complex needs of modern communication through cutting-edge AI solutions. Designed to emulate human-like conversations over phone and digital channels, Syntheia’s platform targets both large enterprises and small-to-medium businesses, which often struggle with customer support inefficiencies and high employee turnover in customer-facing roles. Syntheia’s focus on language processing, tonality, sentiment analysis, and conversational behavior makes its offerings distinctive, providing customers an experience that moves closer to natural human interaction than traditional chatbot solutions.
At the core of Syntheia’s strategy is an innovative approach to AI-driven customer service solutions, a sector experiencing explosive growth. The global conversational AI market, valued at $9.9 billion in 2023, is anticipated to reach a staggering $32.62 billion by 2030. With a projected compound annual growth rate of 21.5 percent, the demand for AI solutions that can handle customer inquiries seamlessly is clear. Factors fueling this market growth include the rising demand for customer-centric interactions, the need for operational efficiency, and cost reductions that companies can realize by automating and enhancing their customer support processes. Syntheia is well-positioned within this trend, providing businesses with tools that reduce onboarding costs, language barriers and other operational challenges while enhancing engagement.
Syntheia is listed on the Canadian Securities Exchange under the ticker symbol SYAI, and its stock is closely held, with a tight float that allows for controlled expansion of shares. Financially, the company is in a solid position with $2 million in cash and no debt, and maintains a well-structured capitalization profile that includes options and warrants. This stable financial foundation provides Syntheia with the means to execute its growth strategy while maintaining flexibility to adapt to market shifts.
Company Highlights
- Syntheia is a conversational AI solution delivering AI-driven, human-like customer service for enterprises and SMBs.
- The AssistantNLP Platform offers 24/7/365 multilingual support, accessible globally.
- Syntheia operates on a freemium revenue model, with scalable plans catering to varied business sizes and needs.
- The conversational AI market is expected to reach $32.62 billion by 2030, with Syntheia well-positioned to capitalize on this growth.
- Syntheia’s algorithms have achieved an 84 percent success rate in data collection and 98 percent in outreach programs, highlighting exceptional efficiency.
- Financially stable, Syntheia has $2 million in cash, no debt and trades on the Canadian Securities Exchange.
Key Technology
Syntheia is a front-runner in conversational AI, employing natural language processing (NLP) algorithms that are continually refined for accuracy and contextual understanding. The platform’s advanced NLP technology, bolstered by proprietary algorithms, enables it to understand and respond to various conversational cues, including tone, sentiment, semantics, and even idiomatic expressions. These sophisticated capabilities make interactions feel more fluid, accurate and responsive, which is particularly advantageous in sectors like healthcare, finance and customer service, where nuanced communication is essential. In fact, Syntheia’s algorithms exhibit impressive efficacy rates, achieving an 84 percent success rate in data collection and a 98 percent success rate in outreach initiatives, demonstrating the system’s effectiveness in real-world applications.
One of the most compelling aspects of Syntheia’s solution is its proprietary AssistantNLP platform, which offers 24/7/365 conversational AI service. The AssistantNLP platform is designed to handle high volumes of customer queries in multiple languages and across industries, ensuring a scalable, reliable and flexible solution for diverse customer needs. Syntheia’s platform is also highly accessible, structured around a freemium revenue model that allows businesses to try the service at no cost and then upgrade based on usage and additional features. The freemium model’s flexibility is essential in broadening Syntheia’s customer base by reducing the initial financial commitment for prospective clients and encouraging growth from smaller firms to larger enterprise accounts.
Management Team
Tony Di Benedetto – Chairman, Chief Executive Officer
Tony Di Benedetto has nearly 20 years of IT entrepreneurship, mergers and acquisitions, and capital markets experience. As a seasoned technology business leader, he has successfully built and brought multiple tech businesses to market.
Richard Buzbuzian – President
Richard Buzbuzian is a capital markets executive with over 25 years of investment experience in Canada and Europe, and operates a family office with an investment portfolio of public and pre-IPO companies. Buzbuzian holds a degree from the University of Toronto.
Paul Di Benedetto – Chief Technology Officer
Paul Di Benedetto is a technology visionary with expertise in diverse innovative technologies, including blockchain and AI. He is responsible for overseeing the ongoing development of patent-approved technology at work from Syntheia.
Veronique Laberge – Chief Financial Officer
Veronique Laberge is a chartered professional accountant and holds the title of auditor. With more than 17 years of experience in professional practice, she specializes in certification mandates and general accounting, and acts as a consultant for public and private companies.
Emilio Iantorno – VP of Product & Experience Strategy
Emilio Iantorno, a 20-year design veteran, specializes in crafting engaging product experiences for diverse audiences and industries. Emilio leads the Syntheia design process, effectively harnessing the best technology to tackle business challenges.
Tech 5: AI Takes Center Stage at CES, NVIDIA Unveils Cosmos Platform
1. AI takes center stage at CES
Unsurprisingly, CES underscored the growing influence of artificial intelligence (AI) across the tech landscape, with AI chips for PCs, new electric vehicles and the influence of robotics on the workforce taking center stage.
AI was prominent, featured in everything from appliances to pets. Following substantial investment, companies are under pressure to demonstrate the value and justify the cost of AI integration in their products.
As mentioned, tech stocks rose on Monday as the event began, with chipmakers like NVIDIA (NASDAQ:NVDA), Broadcom (NASDAQ:AVGO), Micron Technology (NASDAQ:MU), Advanced Micro Devices (AMD) (NASDAQ:AMD) and Taiwan Semiconductor Manufacturing Company (NYSE:TSM) leading the surge.
NVIDIA, whose CEO Jensen Huang gave the keynote address at CES, was a key focus.
Following the company's weaker-than-expected revenue outlook in November, investment interest in AI has been dispersing to include companies such as Broadcom and Marvell Technology (NASDAQ:MRVL), whose share prices increased in the fourth quarter of 2024 while NVIDIA's remained relatively flat.
Broadcom, NVIDIA and Marvell Technology performance, Q4 2024.
Chart via Google Finance.
After a product reveal, NVIDIA saw its share price fall 8.5 percent to US$140.01 on Tuesday (January 7), its largest intraday drop since October 15. Chief among the AI bellwether’s long list of new products are the GeForce RTX 50 series GPUs, built on the Blackwell architecture. The flagship RTX 5090 for demanding workloads will be available this month for US$1,999, while the RTX 5070, a more budget-friendly version, will arrive in February for US$549.
NVIDIA also unveiled Project Digits, a desktop PC designed to empower AI researchers, data scientists and students; it has the ability to run very large AI models on laptops. Developed in collaboration with Taiwan's MediaTek (TPE:2454), the model is equipped with a Grace Blackwell Superchip and runs a version of the Linux operating system. Project Digits essentially puts an AI-powered personal supercomputer within reach for US$3,000 starting in May.
NVIDIA performance, January 6 to 10, 2025.
Chart via Google Finance.
NVIDIA's move highlights a broader trend at CES this year: the rise of AI PCs. AMD, Intel (NASDAQ:INTC) and Qualcomm (NASDAQ:QCOM) all introduced chips designed to bring AI to everyday computing. AMD's high-powered Ryzen CPUs, which will power Dell’s (NYSE:DELL) corporate PCs, reportedly outperform Macs and offer a longer battery life.
Meanwhile, Qualcomm is broadening its business beyond mobile phone chips with the Snapdragon X Platform, an affordable chip for laptops and PCs that will run Microsoft’s (NASDAQ:MSFT) Copilot+ software. The company will also soon release a small desktop computer built with the chip. PC makers including Dell — which announced a rebranding of its PC line — will reportedly offer laptops based on the new product in early 2025.
AMD, Qualcomm and Dell saw share price increases of between 2 and 3.5 percent between Monday and Tuesday. However, Intel’s new processors featuring built-in AI acceleration and a dedicated neural-processing unit in select models weren’t enough to impress investors, and its share price was little changed over the same period.
2. Autonomous vehicles have their moment
While AI PCs generated excitement at CES, another trend emerged: the rise of generative physical AI.
During his keynote, Huang emphasized how this forthcoming shift will revolutionize factory and warehouse automation, a rising subsector he described as "a multi-trillion dollar opportunity."
This sentiment is seemingly shared by OpenAI founder Sam Altman, who wrote in a weekend blog post of a near future where “AI agents join the workforce and materially change the output of companies."
To accelerate this transition, Huang unveiled NVIDIA Cosmos, an open-source platform designed to simulate real-world environments and accelerate the training of physical AI models like robots and cars. Within Cosmos, AI agents can be trained using Nemotron, a new family of large language models optimized for agentic AI. Based on Meta's (NASDAQ:META) Llama models, Nemotron leverages NVIDIA's CUDA and AI acceleration technologies.
“Cosmos will dramatically accelerate the time to train intelligent robots and advanced self-driving cars,” Rev Lebaredian, vice president of omniverse and simulation technology at NVIDIA, said at a press conference on Monday.
Later, news broke of a partnership between NVIDIA and Toyota (NYSE:TM) that will see the carmaker use NVIDIA's autonomous driving chips and software to advance its self-driving cars. NVIDIA also announced a partnership with Uber (NYSE:UBER) to use its drive logs for AI model training.
“After so many years, with Waymo and Tesla's (NASDAQ:TSLA) success, it's very clear (autonomous vehicles) have finally arrived,” said Huang on Monday. Later, during an interview with Yahoo Finance’s Dan Howley, he disclosed that NVIDIA's technology for autonomous driving is projected to generate US$5 billion in annual sales.
3. Bitcoin price falls below US$100,000
The Bitcoin price rose above US$102,000 early on Monday, following a weekend in which the cryptocurrency regained its 50 day simple moving average, an indicator often described as crucial for a continued bull market.
Adding to the momentum was strong speculation that MicroStrategy (NASDAQ:MSTR) was preparing to increase its holdings further after CEO Michael Saylor hinted at a potential acquisition over the weekend.
The company ultimately purchased 1,070 Bitcoins for a total price of US$101 million.
Adding to bullish sentiment was a research report from JPMorgan (NYSE:JPM); it indicates that Bitcoin miners' revenue increased for the second consecutive month in December. The positivity extended to altcoins as Solana’s DEX trading volume exceeded that of Ethereum and Base; the price action prompted analysts to set a US$15 target for XRP.
However, as conflicting US jobs and inflation data rolled in, traders' hopes of an interest rate cut by March diminished. Yields for 10 year Treasuries touched 4.73 percent, resulting in a broad selloff affecting cryptocurrencies and other risk-on assets like tech stocks. The top cryptocurrencies dropped between 4 and 9 percent in early trading on Tuesday.
Bitcoin performance, January 6 to 10, 2025.
Chart via CoinGecko.
US Bitcoin exchange-traded funds (ETFs) saw near-record outflows of US$582 million on Wednesday (January 8) as the downward trajectory continued. Ether ETFs saw substantial outflows totaling US$159.3 million on Wednesday, their largest on record since July. By Thursday (January 9), US$655 million in Bitcoin futures contracts had been liquidated.
Adding to the uncertainty, the US Department of Justice has reportedly been cleared to sell US$6.5 billion worth of Bitcoin seized from Silk Road, which could put downward pressure on Bitcoin’s price.
Altcoins saw greater losses, with XRP being the sole exception.
Ripple’s native cryptocurrency saw periods of recovery on Wednesday after it was reported that CEO Brad Garlinghouse and Chief Legal Officer Stuart Alderoty met with Trump for dinner. Analysts at Cointelegraph project XRP could surge 40 percent if prices can break out of the current “descending triangle” pattern.
Friday’s (January 10) US jobs data release coincided with a 2.24 percent drop in Bitcoin’s price to below US$92,000 before the markets opened, followed by a rise to US$95,000 midday. Bitcoin’s latest downtrend has led market analysts to believe that the coin's price may retest areas around US$90,000 as traders contend with uncertainty regarding tariffs and their effects on the US economy, stoking concerns about the possibility of renewed inflation.
According to Santiment analyst Brianq, Bitcoin's performance can also be partly attributed to decreased purchasing activity by wallets holding between 100 and 1,000 Bitcoin, which drove Bitcoin’s most recent bull cycle.
Don't forget to follow us @INN_Technology for real-time news updates!
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
BlinkLab Limited Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects